Nifurpipone
Nifurpipone is an orally active broad-spectrum antimicrobial agent. Nifurpipone acts against Gram-positive and Gram-negative bacteria, and reduces bacterial loads in systemic, intramuscular and urinary tract infections in mouse models. Nifurpipone can be used in studies related to bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 24632-47-1
- Formula: C12H17N5O4
- Molecular Weight:295.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Nifurpipone (Compound 13) (2.5-160 units) exhibits in vitro antibacterial activity against Escherichia coli 100 (40), Salmonella typhimurium 1090 (40), Pseudomonas aeruginosa H2 (160), Proteus vulgaris OX (80), Micrococcus pyogenes SG511 (20), Streptococcus pyogenes A88 (2.5), and Bacillus subtilis ATCC 9466 (20)[1].
Nifurpipone exhibits antibacterial activity against a variety of Gram-negative and Gram-positive bacteria in vitro, with MIC values ranging from 5 to 160 μg/mL under standard conditions, and retains most of its activity in the presence of 10% bovine serum[2].
Nifurpipone inhibits most of the 70 clinical urinary tract infection strains at a level of MIC ≤100 μg/mL, with the strongest activity against strains of the genera Klebsiella-Enterobacter and Proteus[2].
The in vitro antibacterial activity of Nifurpipone against Staphylococcus aureus SG 511 increases with rising pH, and its MIC value decreases by 100-fold over the pH range of 5 to 8[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Nifurpipone exhibits in vivo antibacterial activity against ascending Proteus vulgaris urinary tract infection in rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 24632-47-1
-
Molecular Weight 295.29
-
Formula C12H17N5O4
-
SMILES
CN1CCN(CC1)CC(N/N=C/C2=CC=C([N+]([O-])=O)O2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Nifurpipone
- 24632-47-1
- Bacterial
- antimicrobial agent
- Escherichia coli 100
- Salmonella typhimurium 1090
- Pseudomonas aeruginosa H2
- Proteus vulgaris OX
- Micrococcus pyogenes SG511
- Streptococcus pyogenes A88
- Bacillus subtilis ATCC 9466
- enera Klebsiella-Enterobacter
- Proteus
- Staphylococcus aureus
- Inhibitor
- inhibitor
- inhibit